News & Events
Immune-Onc Therapeutics, Inc. (“Immune-Onc”) is a clinical-stage cancer immunotherapy company dedicated to the discovery and development of novel myeloid checkpoint inhibitors for cancer patients.
The company aims to translate unique scientific insights in myeloid cell biology and immune inhibitory receptors to discover and develop first-in-class biotherapeutics that disarm immune suppression in the tumor microenvironment. Immune-Onc has a promising pipeline with a current focus on targeting the Leukocyte Immunoglobulin-Like Receptor subfamily B (LILRB) of myeloid checkpoints.
We’re excited about our mission and are committed to sharing updates on our progress.
Press Releases
Phase 1 study of IO-202 in combination with azacitidine currently enrolling newly diagnosed CMML patients
Collaboration to evaluate IO-108 in combination with atezolizumab (Tecentriq®) and bevacizumab (Avastin®) as a potential first-line therapy for hepatocellular carcinoma
News & Events
Ari Mahrer, data reporter for the San Francisco Business Times, took a look at some of the monumental achievements from companies on their women-led life sciences list. Immune-Onc’s recent milestone: received Orphan Drug Designation for IO-202 for the treatment of chronic myelomonocytic leukemia from the FDA.
The FDA has granted IO-202 an orphan drug designation for patients with chronic myelomonocytic leukemia.
One-hour live moderated discussion with The Leukemia & Lymphoma Society's (LLS) Therapy Acceleration Program® (TAP) portfolio partners.
Courtney DiNardo, MD, MSCE, the lead author on a study presented at EHA 2023 evaluating a new therapy for chronic myelomonocytic leukemia and acute myeloid leukemia, discusses the FDA Fast Track Designation for IO-202 and strategies for raising awareness and improving diversity in clinical trials.
Matthew H. Taylor, MD, discusses the preliminary data on the use of IO-108 in advanced solid tumors in a phase 1 study.
AACR 2023: Phase 1 Trial of IO-108, An Antagonist Antibody Targeting LILRB2 (ILT4), as Monotherapy and in Combination with Pembrolizumab in Adult Patients with Advanced Relapsed or Refractory Solid Tumors
Findings from a phase 1 study showed that the fully humanized IgG4 antibody IO-108 was well tolerated and displayed durable responses when given as a monotherapy as well as in combination with pembrolizumab, supporting further development of the agent alone or with PD-1/PD-L1 targeted therapy for patients with advanced solid tumors.
Advances in drug discovery and development were the clear standouts for Bay Area women-led life sciences companies.
Media Contact
Tara Cooper
The Grace Communication Group
tara@gracegroup.us